N/A
Manufactured by Fresenius Kabi USA, LLC
2 FDA adverse event reports analyzed
Last updated: 2026-04-15
BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE include DISEASE PROGRESSION, DRUG INEFFECTIVE FOR UNAPPROVED INDICATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE.
Out of 1 classified reports for BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 2 FDA FAERS reports that mention BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DISEASE PROGRESSION, DRUG INEFFECTIVE FOR UNAPPROVED INDICATION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with BENZALKONIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.